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Summary
Van Buchem disease (hyperostosis corticalis generalis-
ata; OMIM 239100 [http://www3.ncbi.nlm.nih.gov:
80/htbin-post/Omim/dispmim?239100]) is an autoso-
mal recessive disorder characterized by hyperostosis of
the skull, mandible, clavicles, ribs, and diaphyseal cor-
tices of the long bones. The most striking clinical fea-
tures are the enlargement of the jaw and the thickness
of the skull, which may lead to facial nerve palsy, hearing
loss, and optic atrophy. Increased formation, by osteo-
blasts, of qualitatively normal bone has been proposed
as the underlying pathological mechanism, but the mo-
lecular defect is unknown. We studied 11 van Buchem
patients and their highly inbred family, who live in The
Netherlands in a small ethnic isolate, that had a common
ancestor ∼9 generations ago. A genomewide search with
highly polymorphic microsatellite markers showed link-
age to marker D17S1299 on chromosome 17q12-21
(maximum LOD score of 8.82 at a recombination frac-
tion [v] of .01). Analysis of additional markers from that
region delineated a candidate region of !1 cM, between
markers D17S1787 and D17S934. Interestingly, the only
marker not showing recombination with the disease lo-
cus was an intragenic marker of the thyroid-hormone
receptor a1 (THRA1) gene, which generated a LOD
score of 12.84 at . Since thyroid hormones arev  .00
known to stimulate bone resorption, the THRA1 gene
might be involved in the etiology and pathogenesis of
van Buchem disease. Unraveling the underlying mech-
anism for this disorder could contribute to the under-
standing of the regulatory processes conditioning bone
density and the underlying pathological processes.
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Introduction
Van Buchem disease is an autosomal recessive sclerosing
bone dysplasia that van Buchem et al. first described in
1955. They called this condition “hyperostosis corticalis
generalisata familiaris,” but Fosmoe et al. (1968) initi-
ated use of the eponym “van Buchem disease,” which
is widely accepted. The most characteristic feature is
endosteal hyperostosis of the mandible, skull (both the
calvarium and the cranial base), ribs, clavicles, and di-
aphyses of the long bones (van Buchem et al. 1962). Van
Buchem disease therefore has been classified as a cranio-
tubular hyperostosis (Beighton 1988). The characteris-
tics of this group of sclerosing bone diseases is that, in
addition to increased bone density, there is a disruption
of bone contours. Many subperiosteal osteophytes (ex-
ostoses) can form on these altered bones, resulting in a
very rough bone surface. The principal clinical features
are macrocephaly and an impressively enlarged man-
dible, which can be very broad and prognatic. The
weight of the skull and mandible is grossly increased, in
some patients to more than three times the normal
weight. In most cases, the bone anomalies are symmetric
and progressive, starting in the 1st decade of life. Inter-
estingly, van Buchem patients hardly ever have fractures.
Owing to encroachment on the cranial foramina, by the
hyperostotic bone, the clinical complications include cra-
nial nerve paralysis (5th, 7th, 8th, and 10th cranial
nerves), neuralgic pain, sensorineural hearing loss, and
visual problems—such as optic atrophy—that some-
times lead to blindness (van Buchem 1971). Increased
intracranial pressure also has been described (van
Buchem et al. 1955). Surgical treatment for both de-
compression of cranial nerves and recontouring of the
mandible has been performed (Schendel 1988).
The prevalence of van Buchem disease is very low,
with !30 cases reported. Van Buchem et al. (1976) de-
scribed a total of 15 patients, who were all of Dutch
origin. One family with four affected siblings (Dixon et
al. 1982) and a few isolated cases (Lopez et al. 1985;
Miguez et al. 1986; Fryns and Vandenberghe 1988;
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Figure 1 Pedigree including 13 van Buchem patients, over 10 generations. Blackened symbols represent affected individuals. The iden-
tification number of each patient is shown below the symbol. Patient 12 represents case I and patient 13 represents case II from the study by
van Buchem (1971). For the other six patients described previously (patients 3–8), the numbering remained identical. For the 11 patients included
in this linkage study, the alleles for marker D17S1299 are shown below each symbol. In eight patients, marker D17S1299 is homozygous for
allele 3. The heterozygosity in the remaining three patients (9, 10, and 11) could have been caused by one recombination event.
Cook et al. 1989; Bettini et al. 1991) also have been
reported. In addition, as already suggested by Eastman
and Bixler (1977), several case reports have been pub-
lished concerning subjects who probably did not have
van Buchem disease (Dyson 1972; Owen 1976; Ruckert
et al. 1985; Schendel 1988; Rodriguez et al. 1995);
rather, these subjects probably had the more benign, au-
tosomal dominant endosteal hyperostosis, first described
by Worth and Wollin (1966).
On the basis of normal bone structure, the normal
mineral content of bone, and increased alkaline phos-
phatate in serum, van Buchem et al. (1976) have sug-
gested that the disease is due to increased formation of
normal bone. However, the primary defect of van
Buchem disease is unknown.
In order to localize the gene for van Buchem disease,
we performed a genetic linkage study in a small village
located in The Netherlands. This village is an ethnic
isolate with a very high degree of consanguinity. Eight
of the 15 Dutch patients described by van Buchem
(1971) lived in this village and were known to originate
from common ancestors. We restudied this family and
found 11 patients. Six are survivors from the last study
by van Buchem et al. (1976), whereas five new patients
were diagnosed by us.
Subjects and Methods
Patients and Pedigree
The van Buchem–disease pedigree described by van
Buchem et al. (1976) has been extended and now con-
tains 13 affected individuals, of whom 2 (patients 12
and 13) had died by the time of our study. The remaining
11 patients, from seven sibships, were investigated in
this study. Information obtained from an extended ge-
nealogical study, which covered the entire population of
the small village and dated back to the beginning of the
seventeenth century, enabled us to extend the pedigree
described by van Buchem et al. (1976). Family relation-
ships for all 13 patients were documented, and a couple
who were married in 1751 was identified as the common
ancestors for 14 of the 18 parents of the 13 patients (fig.
1). The remaining 4 parents (the mother of patient 1,
the mother of patients 6–8, the mother of patient 12,
and the father of patient 13) could not be linked to these
common ancestors. Six of the patients (patients 3–8)
have been described in detail (van Buchem 1971; van
Buchem et al. 1976), whereas five patients (patients 1,
2, and 9–11) were diagnosed in this study (fig. 2). The
diagnosis of van Buchem disease was based mainly on
Figure 2 Clinical pictures of seven patients showing characteristic features of van Buchem disease. Frontal (A) and lateral (B) views of patient 3. This patient, at age 65 years, was the oldest
patient studied. C–G, Pictures of the five new van Buchem patients (patients 1, 2, and 9–11, respectively). All patients showed the characteristic features of protruding chin, high forehead, and facial
nerve paralysis, as illustrated in panel C.
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Figure 3 X-rays showing generalized sclerosis in van Buchem patients. A, Lateral view of the elbow, showing diffuse diaphyseal sclerosis.
The cortex is thickened, and there is narrowing of the medullary canal. B and C, Anteroposterior and lateral views of the skull, showing
extensive sclerosis of the calvarium and the skull base, enlargement of the mandible, and obliteration of the paranasal and mastoid air spaces
(Van der Wouden 1971).
the phenotypic abnormalities of the skull and mandible,
facial nerve involvement, and radiological pictures of the
skeleton. Facial nerve grading (House 1983) proved to
be a good diagnostic criterium, since severe dysfunction
(grade V) on at least one side was seen in all 11 patients
examined, with the exception of patient 8, who showed
a moderately severe dysfunction (grade IV) on both
sides. The most prominent features were found in patient
3 (fig. 2A and B), who is the oldest (age 65 years) among
the patients. This suggests that, in van Buchem patients,
the skull and mandible grow continuously throughout
life, which was confirmed by comparison with pictures
of patients at a younger age. Radiological examination
of the van Buchem patients revealed increased bonemass
of the long bones (fig. 3A) and hyperostosis of the skull
and mandible (fig. 3B and C; fig. 4). In four of the five
new patients, minimal sensorineural hearing loss was
found. This may be due to compression of the 8th cranial
nerve.
Genotyping
Genomic DNA was obtained from peripheral blood
leukocytes, by standard techniques.Microsatellitemark-
ers were analyzed by use of an automated DNA-se-
quencing apparatus (Applied Biosystems [model 373]),
using fluorescently labeled primers. For allele identifi-
cation, GENESCAN and GENOTYPER software was
used in combination with the Linkage Designer program
(Van Camp et al. 1997). The Cooperative Human Link-
age Center Human Screening Set (Weber version
6)—which contains 391 markers, covering the entire hu-
man genome, with an average spacing of 10 cM—was
used in a genomewide linkage analysis. The markers are
mainly tri- and tetranucleotides and have an average
heterozygosity of 76%. PCR reactions were performed
by use of a Hybaid OmniGene thermal cycler (Biozym)
containing 80 ng genomic DNA, 200 mM each dNTP,
1# PCR buffer, 2.5 mM MgCl2, 0.5 units AmpliTaq
Gold DNA polymerase, and either 24 ng each primer,
for blue (FAM-labeled) and green (TET-labeled) mark-
ers, or 48 ng each primer, for yellow (HEX-labeled)
markers, in a total volume of 20 ml. After initial dena-
turation at 94C for 5 min, the samples underwent 30
cycles of amplification (94C for 1 min, 55C for 1 min,
and 72C for 1 min), with a final extension at 72C for
30 min. Two multiplex reactions were performed, one
containing all blue and green markers and the other
containing yellow markers. The two separate multiplex
reactions were brought together by pooling of 5 ml blue
and green markers with 10 ml yellow markers. Loading
samples were prepared by addition of 4 ml deionized
formamide and 0.7 ml TAMRA-2500 internal size stan-
dard (Perkin Elmer–Applied Biosystems) to 1.5 ml of the
pooled reaction. After denaturation at 94C for 5 min,
2.5 ml of each sample was loaded on a polyacrylamide
gel and was electrophoresed in accordancewith theman-
ufacturer’s instructions.
Radioactive PCR amplification (Hughes 1993) of
polymorphic markers was performed by use of 80 ng
DNA template and 4 pmol each primer, in a total volume
of 20 ml. Sequences for primer pairs are listed in the
Genome Database (http://gdbwww.gdb.org/). Prior to
Figure 4 Skull and mandible of one of the patients described originally by van Buchem et al. (1955). This skull of a 52-year-old female case weighs 2,357 g. Frontal (A) and lateral (B) views
show the markedly enlarged and thickened hyperostotic mandible with many bone excrescences. The entire skull, including the zygomatic ouch nose, is severely thickened and has a rough surface
covered with flat excrescences or exostoses. Sutures have disappeared, owing to new bone formation. The orbital, foramen opticum, and nasal openings are narrowed. The skull shows impressive
thickening (C), and the mandible has a blown-up appearance (D and E), owing to massive enlargement of the entire mandible, which is covered with bony excrescences.
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Table 1
Pairwise LOD Scores between Van Buchem Disease and Markers
from Chromosome 17q21-22
MARKER
LOD SCORE AT v 
.00 .01 .05 .10 .20 .30 .40
D17S1851 7.99 9.79 9.36 8.12 5.56 2.90 .89
D17S1814 6.75 8.56 8.19 7.13 4.73 2.45 .80
D17S800 6.12 7.92 7.53 6.46 4.09 1.94 .55
D17S1787 6.76 8.57 8.20 7.14 4.72 2.41 .77
D17S934 13.35 13.04 11.76 10.12 6.81 3.64 1.16
D17S1861 8.73 10.47 9.98 8.76 5.97 3.18 .98
D17S791 6.08 9.54 9.79 8.90 6.38 3.61 1.31
D17S806 1.02 7.80 8.69 8.06 5.80 3.21 1.03
Table 2
Haplotypes for Polymorphic Markers from the Chromosome
17q21-22 Region, in 11 Patients from the Van Buchem Family
MARKER
HAPLOTYPE, IN PATIENT
1 2 3 4 5 6 7 8 9 10 11
D17S1851 1 1 1 1 1 1 1 1 1 1 1 3 1 3 1 3 1 2 1 2 1 2
D17S1814 2 2 2 2 2 2 2 2 2 2 2 5 2 5 2 5 2 1 2 1 2 1
D17S800 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 1 3 1 3
D17S1787 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2 3 2 3 2
D17S934 3 6 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
D17S1861 2 8 2 2 2 2 2 6 2 6 2 2 2 2 2 2 2 2 2 2 2 2
D17S791 6 8 6 2 6 6 6 8 6 8 6 6 6 6 6 6 6 6 6 6 6 6
D17S806 1 1 1 2 1 1 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1
NOTE.—Underlined alleles indicate those that are divergent from
the shared haplotype.
amplification, one primer was end-labeled with 32P with
polynucleotide kinase (Pharmacia). Radioactive PCR
conditions were similar to the conditions used for the
fluorescently labeled markers, with the exception that
the number of PCR cycles was 26. Primers used for
analysis of an intragenic marker of the thyroid-hormone
receptor a1 (THRA1) gene have been described else-
where (Futreal et al. 1992).
Genome Search
First, we conducted a genome search with DNA from
the 11 patients only, including one sibship of 3 patients,
two sibships of 2 patients, and four affected distant rel-
atives. For markers suggestive of linkage, 22 additional
individuals were analyzed. These included the 11 avail-
able siblings of the patients, the parents of patients 2
and 6–11, and, finally, the father and 2 siblings of the
mother of patient 2 (fig. 1). Informed consent was ob-
tained from all individuals.
Linkage Analysis
Linkage analysis was performed by use of the FAST-
LINK programs (Cottingham et al. 1993; Scha¨ffer et al.
1994). MLINK two-point linkage analysis between the
microsatellite markers and the disease was performed
under the assumption that van Buchem disease is an
autosomal recessive disease with a disease frequency of
1/100,000. Allele frequencies of the microsatellite mark-
ers were set at 1/n, where n is the published number of
alleles for each marker. Linkage analysis was performed
with consideration of the known consanguineous rela-
tionships shown in the pedigree in figure 1.
Results
Genome Search
After testing 391 polymorphic tri- and tetranucleotide
markers, which covered the entire genome, we analyzed
the allele distribution of the 11 patients. Within the three
sibships, only 15 markers were free of recombinations.
D17S1299 was most suggestive of linkage, since it was
homozygous for one allele in eight patients and heter-
ozygous in the remaining three patients (fig. 1). More-
over, the heterozygosity in the three patients could be
explained by a single recombinational event that had
occurred several generations back. The suggestion that
van Buchem disease is linked to the chromosomal region
around D17S1299 was confirmed by linkage analysis.
After inclusion of the 22 additional individuals, a LOD
score of 8.82 at a recombination fraction (v) of .01 was
obtained.
Delineation of the Candidate Region
To delineate the candidate region more precisely, we
analyzed eight markers from the highly saturated Ge´-
ne´thon microsatellite map (Dib et al. 1996). D17S1299
is not precisely mapped on the Ge´ne´thon map but was
assigned to a 1.5-cM interval between D17S1814 and
D17S932 (see http://www.CHLC.org/ABI/ABIRefMaps
.html). The two-point LOD scores provided evidence for
linkage of van Buchem disease to this chromosomal re-
gion (table 1). Haplotype analysis of all affected chro-
mosomes in the 11 patients enabled us to delineate the
candidate region (table 2). A shared recombined hap-
lotype in patients 9–11 excludes the region proximal to
D17S1787 as the region harboring the disease gene. A
recombination in patient 1 makes D17S934 the flanking
marker on the distal side of the candidate region. There-
fore, the 0.7-cM region between D17S1787 (proximal
side) and D17S934 (distal side) contains the van
Buchem–disease gene (fig. 5 and table 2). Since these
markers are cytogenetically close to the border of chro-
mosomal bands 17q12 and 17q21, the van
Buchem–disease gene must be located in the chromo-
somal region 17q12-q21.
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Figure 5 Delineation of the genetic candidate region for the van
Buchem gene, on chromosome 17, by analysis of key recombinants.
The blackened bars represent the regions containing the disease gene,
whereas the unblackened bars represent excluded regions. The vertical
lines represent regions that were uninformative. A recombination event
in patients 9–11 excludes the region proximal to D17S1787, whereas
a recombination with D17S934 in patient 1 excludes the region distal
to D17S934. The remaining candidate region, between D17S1787 and
D17S934, spans 0.7 cM on the genetic map.
Analysis of an Intragenic Marker of the THRA1 Gene
Since the THRA1 gene has been assigned to 17q11.2-
12 (Fain et al. 1991) and since thyroid hormones are
known to stimulate bone resorption (Mundy et al.
1976), we analyzed an intragenic marker for the THRA1
gene (Futreal et al. 1992). No recombinations between
the disease and this marker were detected (data not
shown), and a two-point LOD score of 12.84 at v 
was obtained..00
Discussion
Bone is a dynamic tissue that is constantly remodeled
throughout life by two processes, bone formation and
bone resorption. The balance of these processes is under
the control of both systemic factors (such as parathyroid
hormone and vitamin D) and local factors (such as trans-
forming growth-factor b and fibroblast growth factor)
(Canalis 1983; Canalis et al. 1993). Disruption of this
balance can cause a diverse spectrum of pathological
conditions. At one end of this spectrum are conditions
that cause decreased bone density, such as osteoporosis.
At the other end of this spectrum are diseases that cause
increased bone mass or density, caused by increased bone
formation or reduced bone resorption (Whyte 1997).
Not all of these diseases are determined genetically, but
120 distinct genetic entities have been described (Whyte
1996). The disorders causing high bone mass are called
“osteoscleroses” if trabecular bone is increased and “hy-
perostoses” if cortical bone is increased (Beighton 1988).
They include conditions such as osteopetrosis, endosteal
hyperostosis, and pycnodysostosis, as well as many oth-
ers. Thus far, the molecular bases of only two conditions
causing increased bone mass have been unraveled
(Whyte 1997). First, an autosomal recessive form of os-
teopetrosis with renal tubular acidosis and cerebral cal-
cification has been shown to be caused by inactivating
mutations within the carbonic anhydrase II gene (Sly et
al. 1983). Second, in 1996, the cathepsin K gene was
identified as the disease-causing gene in pycnodysostosis
(Gelb et al. 1996), a rare autosomal recessive condition
that might have affected the French impressionist painter
Henry Toulouse-Lautrec. Two more gene locations caus-
ing increased bone mass have been reported recently, one
for an autosomal dominant form of osteopetrosis (Al-
bers-Scho¨nberg disease), at chromosome 1p (Van Hul et
al. 1997), and one for a gene causing high bone mass,
at chromosome 11q (Johnson et al. 1997). In general,
however, positional cloning strategies have only started
to unravel the molecular genetics of sclerosing bone
disorders.
In this study, we were able to find a locus for another
type of sclerosing bone disorder, van Buchem disease,
or endosteal hyperostosis. Bone tissue in van Buchem
disease has a normal structure, with little modeling de-
fect. The underlying mechanism has been suggested, by
van Buchem et al. (1976), to be due to increased oste-
oblast activity, but little pathological or biochemical ev-
idence has been provided to support this hypothesis.
Van Buchem disease is rare, with !30 patients de-
scribed. Most patients (a total of 15) have been reported
by van Buchem et al. (1976) and were of Dutch descent.
Eight patients from this group and five new patients,
from this study, are all living in a small village. This
village was an island until 1941, when part of the sur-
rounding Zuyderzee was reclaimed and the village be-
came a port. The current population is ∼15,000 indi-
viduals, almost all of whom are descendents from only
151 inhabitants that survived the plague in 1637. The
community was and still is isolated geographically, re-
ligiously, and professionally from the rest of The
Netherlands.
This inbred van Buchem–disease pedigree now in-
cludes 13 patients with a common ancestor. As would
be expected, when the structure of the pedigree is con-
sidered, high LOD scores for linkage to the disorderwere
found, and a very small candidate region of 0.7 cM,
between markers D17S1787 and D17S934, was delin-
eated (fig. 5). No additional markers between these two
flanking markers are currently available, so that, for
now, the candidate region cannot be narrowed further.
Many genes, such as EDH17B, ERBB2, GCSF, RARA,
and THRA1, are assigned to the chromosomal region
17q12-q21 (Black et al. 1993). However, detailed phys-
ical mapping of these genes, relative to the small can-
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didate region of 0.7 cM, will reduce dramatically the
number of candidate genes. Of the genes mapping to
human chromosome 17q12-21 or to the synthenic re-
gion on mouse chromosome 11, the THRA1 gene is the
most likely, since thyroid hormones are known to stim-
ulate bone resorption (Mundy et al. 1976). A highly
polymorphic intragenic marker for the THRA1 gene did
not show any recombination with the disease, since it
was homozygous in all patients (data not shown). How-
ever, previous genetic studies mapped the THRA1 gene
proximal to marker D17S800, indicating that this gene
lies outside the candidate region (Anderson et al. 1993).
With regard to this study, homozygosity of this THRA1
marker in all patients could be explained by uninform-
ative key recombinants. Detailed physical mapping, of
the THRA1 gene and the other genes, relative to the
candidate region is currently being performed.
Van Buchem disease belongs to the group of endosteal
hyperostoses. The correct diagnosis of these hyperos-
toses is often hard to make, and the nomenclature is
sometimes confusing. The clinical symptoms of van
Buchem disease also resemble those of sclerosteosis. This
autosomal recessive condition is also characterized by a
massive overgrowth of the mandible and sclerosis of the
skull resulting in cranial nerve compression and in-
creased intracranial pressure (Beighton et al. 1977). In
some patients with sclerosteosis, gigantism and syndac-
tyly, two symptoms that have not yet been reported for
van Buchem disease, are also found. Most of the scle-
rosteosis cases are found in the Afrikaner population of
South Africa, with 140 patients described (Beighton et
al. 1984). On the basis of (1) the close clinical resem-
blance between van Buchem disease and sclerosteosis
and (2) the Dutch origin of the majority of patients with
these diseases, Beighton et al. (1984) postulated that
these conditions should be lumped together. This is cor-
roborated by the report of a sclerosteosis family in a
region of Brazil that was occupied by the Dutch in the
seventeenth century (Alves et al. 1982). The localization
of the van Buchem–disease gene will allow testing of the
hypothesis that dominant endosteal hyperostosis and/or
sclerosteosis are allelic to van Buchem disease.
Because van Buchem disease has an autosomal reces-
sive mode of inheritance, it is likely that the disease-
causing mutation(s) leads to loss of function of the van
Buchem gene. This would imply that the physiological
function of the gene is to inhibit bone formation or to
stimulate bone resorption. The clinical observation that
the hyperostosis observed in van Buchem disease pro-
gresses with age suggests that the van Buchem gene is
not a developmental gene but a gene that is very actively
involved in bone metabolism at an older age. Antisense
treatment of the van Buchem gene therefore might be-
come a form of gene therapy for fractures and diseases
with low bone density.
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